1 Title: Comprehensive large-scale nucleic acid testing strategies support China's sustained

2 containment of COVID-19

3 Zhongjie Li^{1†}, Fengfeng Liu^{1†}, Jinzhao Cui¹, Zhibin Peng¹, Zhaorui Chang¹, Shengjie Lai², Qiulan

4 Chen¹, Liping Wang¹, George F. Gao^{3,4}, Zijian Feng^{3*}

Affiliations: ¹ Division of Infectious disease, Key Laboratory of Surveillance and Early
Warning on Infectious Disease, Chinese Center for Disease Control and Prevention.²
WorldPop, School of Geography and Environmental Science, University of Southampton, UK.
³ Chinese Center for Disease Control and Prevention, Beijing, China. ⁴ CAS Key Laboratory of
Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of
Sciences, Beijing, China.

- 11 **†**:These authors contributed equally.
- 12 Senior author: George F. Gao
- 13 * Correspondence to: Dr. Zijian Feng, No.155 Changbai Road, Changping District, Beijing,
- 14 China, 102206; Email: fengzj@chinacdc.cn
- 15

16

- 17
- 18 19
- 20
- -
- 21
- 22

23 To the Editor - Following identification and initial characterization of COVID-19 in late 24 December 2019 and early January 2020, China's containment goal has been complete 25 interruption of local transmission of SARS-COV-2¹. The nationwide epidemic wave centered 26 on Wuhan was contained by April 2020 with non-pharmaceutical interventions (NPIs) alone, 27 but was associated with economic loss - China's first-quarter gross domestic product (GDP) fell 28 6.8% compared with first-quarter 2019². Since containment, there have been numerous 29 outbreaks in China caused by imported viruses with local spread, varying in size from seven to 30 1,200 cases, all stopped with NPIs alone³. Sustained containment has high socioeconomic value 31 - economic activities recovered rapidly with a GDP increase of 3.2% during April-June 2020 32 and 4.9% during July-September²; government's response to the pandemic was perceived positively by the Chinese public⁴. In this letter, we describe two large-scale PCR-based testing 33 34 strategies which played critically important roles in sustaining containment since last April in 35 mainland China - routine active PCR-based screening, and mass PCR testing during outbreak 36 response.

37 With virtually all of China's population susceptible to SARS-CoV-2 prior to induction of any vaccine-induced population immunity⁵, imported viruses pose an enormous threat to 38 39 containment. All incoming international travelers, workers handling imported goods, medical 40 center outpatients with fever or respiratory symptoms, and medical staff caring for patients 41 with fever or infectious diseases are actively screened with PCR to determine if they are 42 infected. Incoming travelers have been required to quarantine at designated hotels for 14 days 43 following entry into China, during which time they are tested at least twice. As of 30 44 November 2020, 3,866 SARS-CoV-2-infected travelers were diagnosed, preventing seeding of 45 virus in susceptible communities (Figure).

46 Outbreak investigations in Beijing and Dalian found that food contamination could 47 potentially transmit SARS-COV-2^{6,7}. Isolation of viable virus in outer packages of imported 48 seafood in Qingdao strengthened the evidence for such transmission. Workers handling 49 imported goods are now required to be tested weekly for SARS-COV-2, preventing several importation-related outbreaks: for example, four dockworkers were found to have become
infected in December in Dalian, and an outbreak investigation in Kashgar, Xinjiang found
SARS-COV-2 importation via a contaminated cross-border truck.

Fever clinics have long been established in secondary and tertiary hospitals. Anyone with fever seeking healthcare is screened by PCR. Medical facilities admit anyone with suspected COVID-19, unexplained pneumonia, or severe acute respiratory tract infection and test the patients and accompanying persons with PCR. This screening strategy has identified index cases of several outbreaks - Xinfadi market in Beijing, Dalian, Pudong airport⁸, Qingdao⁹, and Manchuria.

59 Routine testing requires many PCR tests. Laboratories combine five or ten specimens and 60 test the combination for SARS-CoV- 2 RNA as an efficiency and cost-saving measure. If the 61 combination tests positive, individuals whose samples were combined are tested separately to 62 identify the infected individual(s). With a 10:1 pooled sampling approach, the average cost 63 per person tested is approximately 9 RMB yuan (\$1.50 USD) in China.

Routine PCR testing is augmented with testing of all close contacts of an infected
person. Since September 2020, all close contacts of infected individuals have been required to
be tested three times during a 14-day centralized quarantine period - day 1 or 2, one day later,
and day 14.

Mass, community-wide PCR testing during or following outbreak response has proven to be a useful strategy to identify infected individuals, including those with no symptoms, and to determine whether a community is free of SARS-CoV-2. Once a local outbreak is identified, geographic jurisdictions are classified by epidemiologists into regions at low, moderate, or high-risk of virus transmission. Persons in high-risk settings are tested individually. In moderate-risk areas, a 5:1 or 10:1 pooled sampling approach is used to reduce the number of tests.

The first citywide mass screening was performed between May 14 and June 1, 2020 in
Wuhan city, testing nearly 10 million people with PCR and identifying 300 asymptomatically-

77 infected individuals for quarantine. The testing results were used to support full reopening of local socioeconomic activities¹⁰. Large screening programs have been implemented following 78 79 local case reports that indicated possible community transmission. For instance, during the 80 Beijing Xinfadi outbreak, 11.9 million persons were tested between 11 June and 14 July 2020; 81 in Dalian, 4.5 million persons were tested between 26 and 31 July; and in Qingdao, 10.9 82 million persons were tested between 11 and 16 October⁹. These large-scale, population-wide 83 screenings contributed to case finding and rapid control of epidemics and provided evidence for 84 government to reopen economic activities.

Timeliness of PCR test results varies by testing purpose and epidemiologic situation. For members of the public who request PCR testing but have no symptoms or exposure history, results are to be reported within 24 hours. Results from outpatients, inpatients, caregivers, close contacts of confirmed cases, and persons residing in high-risk areas in a local outbreak setting are to be reported within 12 hours. Results for patients in fever clinics and emergency departments are to be reported within 6 hours.

In China's new-normal situation, comprehensive, active, and innovative PCR-testing
strategies are performed for targeted groups and in outbreak settings, ensuring timeliness of
early case detection and interruption of local outbreaks - essential ingredients in the prevention
and control strategy. Maintenance of containment has greatly reduced the impact of COVID19 in terms of suffering, lives lost, and socioeconomic progress.

96 The introduction of COVID-19 vaccines globally and in China will undoubtedly improve 97 epidemiological situations. PCR testing strategies will be adjusted to fit the changing 98 epidemiological situations in China – likely one in which few or fewer NPIs will be needed for 99 effective epidemic control. Inexpensive, readily available, and rapid PCR testing will continue 100 to be essential for sensitive SARS-CoV-2 virus surveillance well into the future. Throughout 101 2020, PCR testing served the public well, helping to make and keep China nearly free of SARS-102 CoV-2, and providing socioeconomic space and time for vaccine development and long-term 103 prevention and control of COVID-19.

104 Acknowledgements

- 105 We are grateful to Dr. Lance Rodewald for his contribution on the content and text improvement
- 106 of this letter.

107 Author contributions

- 108 Zhongjie Li, Zijian Feng and George F. Gao designed and supervised the study. Zhongjie Li and
- 109 Fengfeng Liu wrote the manuscript; Jinzhao Cui designed and draw the figure. Zhibin Peng,
- 110 Zhaorui Chang, Qiulan Chen, Liping Wang participated in literature review and data collection.
- 111 Shengjie Lai, George F. Gao commented on and revised drafts of the manuscript.

112 Competing interests

113 The authors declare no competing interests.

114

115 **References**

- ¹ Li, Z., et al. *Lancet* **396**, *63-70* (2020).
- ² National Bureau of Statistics of China, accessed 16 February 2021;

http://www.stats.gov.cn/tjsj/zxfb/202010/t20201020_1794939.html

³ Zheng, C., et al. *China CDC Weekly* **2**,902-905 (2020).

- ⁴ Lazarus, J.V., et al. *PloS one* **15**, e0240011 (2020).
- ⁵ Li, Z., et al. *The Lancet Regional Health. Western Pacific* **8**, 100094 (2021)
- ⁶ Pang, X., et al. *National Science Review***7**,1861–1864 (2020).
- ⁷ Zhao, X., et al. *China CDC Weekly* **2**,658-660 (2020).
- ⁸ Fang, F., Song, Y., Hao, L., Nie, K. & Sun, X. China CDC Weekly **47**,910-911 (2020).
- ⁹ Xing, Y., Wong GWK, Ni W, Hu, X, Xing. N. Engl. J. Med. 383, e129-e129 (2020).

¹⁰ Cao, S., et al. *Nature communications* **11**, 5917-5917 (2020).

Figure legend

Local and imported COVID-19 cases from 1 April 2020 to 30 November 2020, with

outbreaks and mass PCR test strategies indicated.

No. of reported cases

